Quick Answer
PDS Biotechnology Corp reported Operating Income Loss of -$31.54 million for the year ending 2025.
- PDS Biotechnology Corp showed an increase of +13.2% in Operating Income Loss from 2024 to 2025.
- This data is from PDS Biotechnology Corp's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), PDS Biotechnology Corp's Operating Income Loss has declined by 386.2%.
- Historical annual values: Fiscal year 2025: -$31.54 million | Fiscal year 2024: -$36.32 million | Fiscal year 2023: -$43.05 million | Fiscal year 2022: -$41.67 million | Fiscal year 2021: -$21.44 million | Fiscal year 2020: -$14.90 million | Fiscal year 2019: -$21.03 million | Fiscal year 2018: -$3.65 million | Fiscal year 2017: -$51.97 million | Fiscal year 2016: -$39.51 million | Fiscal year 2015: -$26.50 million | Fiscal year 2014: -$13.19 million | Fiscal year 2013: -$6.49 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: